Full Text View
Tabular View
No Study Results Posted
Related Studies
Radium-223 in Patients With Hormone Refractory Prostate Cancer (HRPC) and Skeletal Metastases
This study has been completed.
Study NCT00667537   Information provided by Algeta ASA

First Received on April 24, 2008.   Last Updated on June 8, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hormone Refractory Prostate Cancer
Bone Metastases
Additional conditions recognized in this trial
Bone Marrow Diseases
Bone Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Prostatic Neoplasms
More general conditions related to this trial
Bone Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Alpharadin TM (Radium-223)
Additional drug interventions recognized in this trial
Hormones
More general drug interventions related to this trial
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Algeta ASA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services